| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FRAT-1 |
| Entrez GeneID | 10023 |
| WB Predicted band size | Calculated MW: 29 kDa; Observed MW: 29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human FRAT1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4条关于FRAT1抗体的参考文献示例(内容为虚构模拟，仅作格式参考)：
1. **文献名称**: "FRAT1 Antibody Validation in Wnt/β-catenin Signaling Studies"
**作者**: Smith J, et al.
**摘要**: 本研究利用兔源多克隆FRAT1抗体，通过Western blot和免疫共沉淀技术验证了FRAT1在Wnt信号通路中对β-catenin稳定性的调控作用，表明其在结直肠癌细胞中促进肿瘤生长。
2. **文献名称**: "Development of a Monoclonal FRAT1 Antibody for Prognostic Applications in Lymphoma"
**作者**: Chen L, et al.
**摘要**: 开发了一种高特异性小鼠单克隆FRAT1抗体，用于免疫组化分析，证实FRAT1在弥漫大B细胞淋巴瘤中高表达，且与患者不良预后显著相关。
3. **文献名称**: "FRAT1 Interaction Networks Revealed by Immunoprecipitation-Mass Spectrometry"
**作者**: García R, et al.
**摘要**: 结合FRAT1抗体进行免疫沉淀-质谱分析，揭示了FRAT1与GSK3β及Axin1的相互作用机制，为靶向Wnt通路的药物开发提供新靶点。
4. **文献名称**: "Optimization of FRAT1 Antibody for Flow Cytometry in Hematopoietic Stem Cells"
**作者**: Kim S, et al.
**摘要**: 优化了FRAT1抗体的染色条件，成功应用于流式细胞术检测造血干细胞中FRAT1的表达动态，发现其与干细胞自我更新能力正相关。
(注：以上文献为模拟生成，实际引用需查询真实数据库如PubMed)
The FRAT1 (Frequently Rearranged in Advanced T-cell lymphomas 1) protein, encoded by the *FRAT1* gene, is a key regulatory component in the Wnt/β-catenin signaling pathway. It acts as a positive modulator by binding to glycogen synthase kinase-3β (GSK3β), thereby preventing the formation of the β-catenin destruction complex. This inhibition stabilizes β-catenin, enabling its nuclear translocation to activate Wnt target genes involved in cell proliferation, differentiation, and survival. FRAT1 overexpression is implicated in various cancers, including T-cell lymphomas, hepatocellular carcinoma, and breast cancer, where it contributes to tumor progression and poor prognosis.
FRAT1 antibodies are essential tools for studying its expression, localization, and functional roles in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect FRAT1 in tissue samples, cell lines, or experimental models. Researchers employ FRAT1-specific antibodies to explore its oncogenic mechanisms, interactions with signaling partners, and potential as a therapeutic target. Additionally, they aid in evaluating FRAT1's diagnostic or prognostic value in cancer biomarkers. Commercial FRAT1 antibodies are typically raised against conserved epitopes, ensuring cross-reactivity in human, mouse, and rat samples. Validation includes testing for specificity via knockout controls or siRNA knockdown. As dysregulated Wnt signaling is a hallmark of many diseases, FRAT1 antibodies remain critical for advancing research in oncology and developmental biology.
×
